Benitec Biopharma Inc. · NASDAQ:BNTC
Benitec Biopharma — Benitec — Shareholder Meeting (November 2006)
15 slides from Benitec Biopharma's shareholder meeting presentation, Nov 30, 2006
Slide 1: Benitec Ltd (ASX:BLT) Annual General Meeting
Benitec Ltd (ASX:BLT) Annual General Meeting 30 November 2006
Slide 2: Benitec (ASX:BLT) Corporate Overview
Benitec (ASX:BLT) Corporate Overview e Benitec are pioneers in the RNA interference (RNA\) field and are using proprietary technologies to develop RNAi drugs for unmet medical needs such as HIV and Hepatitis C (HCV) in mid 2006 the new Board and advisory team commenced a strategic review to refocus
Slide 3: Corporate Overview
Corporate Overview e ® Pioneers in RNAi since 1997 ® Seminai patents in DNA-directed RNA interference (ddRNAI) technology ® Multiple licensees for commercial and therapeutic uses of RNAI ®* Focused on developing treatments for commercially attractive, major, life-threatening diseases ® Listed on the
Slide 4: Mechanism of RNA interference (RNAi)
Mechanism of RNA interference (RNAi) ® Natural mechanism ® Rapidly deployed -) 8 Highly specific siRNA or Ir ® Catalytic Activated RNAi Target Binding Target Destruction y tee
Slide 5: Advantages of ddRNAi technology
Advantages of ddRNAi technology e Compared with alternative gene silencing technologies eg antisense and siRNA the Benitec ddRNAiI technology has the following advantages: - Lower cost and ease of preparation ~ More versatile delivery options ~ The ability to silence genes in whole organisms (transg
Slide 6: RNAi Market opportunity
RNAi Market opportunity e «The RNAi market achieved global sales of just over USD$1bn in 2004 *Projected to reach USD$2.5bn by 2010 «Competitive dynamic market environment Hew roles WOE PONE AROSE BUDGE 2OQ7E 2008 2O03E Tote market walue=$38 million Beitr
Slide 7: Market Reward for RNAi
Market Reward for RNAi Benitec, Alnylam, and Sirna were featured on a BIO 2006 panel discussion ~ moderated by a Senior Analyst at Piper Jaffray as the leading companies worldwide in intellectual property and development of RNAi. Alnylam Pharmaceuticals Sirna Therapeutics * Current market cap US$654
Slide 8: Intellectual Property
Intellectual Property An industry-leading patent portfolio in RNAI™> DNA-directed RNAi in plants DNA-directed RNAI in tissue RNAi in mouse model of human disease (Graham et al.) ”..culture and mammals." (McCaffrey and Kay) (Graham et al.) | Plant 9°. . - - . co-suppression RNAi in nematodes. RNAi in
Slide 9: Benitec IP Position
Benitec IP Position 7 Extract from Companies & Markets, Jain PharmaBiotech, August 2006 RNAI patents - Among the companies, Alnylam and Benitec have strong patent positions. * On 5 June 2003, Benitec Lid was granted its core technology patents in the US and the UK. * These patents, with priority dat
Slide 10: Licensees and Strategic Partners
Licensees and Strategic Partners 2) * Therapeutic Use of ddRNAiI eo fe, a - Tacore Therapeutics Lb Al nylam. ~ Alnylam Pharmaceuticals CORMBIMATRIX, ~ CombiMatrix Dio ease ~ Revivicor * Research Reagent or Transgenic Animal Product Development and Sales ~ Sigma-Aldrich ote ~ @ ~ genonay Revivicor Am
Slide 11: Benitec Capital Structure
Benitec Capital Structure ~) * Shares outstanding 188.47 M * Share price as of 29th Nov 2006 AS$0.062 * Market capitalization A$11.68M * Options/warrants outstanding 59.8M * Fully diluted shares 232.5M ConmSec.+ @ PARHEGH crans cee ence crecemnmsnscien ai ole hcl ol as Nov Dee an |. Feb War. Apr May
Slide 12: Recovery plan
Recovery plan 7) Refocus business with move to lower cost model of value creation with co-investment and/or licensing to bring in additional revenues Complete a successful capital raising to fund turnaround Re-establish presence in Australia and appoint Australian based management team Commence Phas
Slide 13: Risk and Mitigation
Risk and Mitigation e * Risks ~ UPSTO re-examination and Nucleonic litigation ~ Cash position * Mitigation ~ Capital raising ~ Low cost model ~ Continuing to seek advice from patent attorneys and provide input to ensure the strategy for prosecution of the core ddRNAji patent applications optimizes t
Slide 14: Compelling opportunity for investment
Compelling opportunity for investment Opportunity for investors — dynamic area ~ Undervalued ~ Nobel Prize Fire and Mello — validation of science ~ Merck purchase of Sirna for 1.1B 2x market cap — validation by business Strong IP position ~ Global rights to human therapeutics High profile license de
Slide 15: Thank you
Thank you Sue MacLeman +61 3 437211200 smacleman@benitec.com www.benitec.com